Research directory

Clinical trials

Find trials by company, ticker, title or NCT ID.

Filters
Reset
1,647 trials match your filters.
TrialSponsorPhaseStatusPrimary completion
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)NCT07076407XENEPhase 3Recruiting2027-05Estimated
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767OLMAPhase 3Recruiting2028-12Estimated
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled HypertensionNCT07090161Vanda PharmaceuticalsPhase 2Recruiting2026-10Estimated
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque PsoriasisNCT07090330ORKAPhase 2Active not recruiting2026-03-25Actual
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia PsychosisNCT07095465ACADPhase 3Enrolling by invitation2029-02Estimated
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous NephropathyNCT07096843CLYMPhase 2Recruiting2027-10Estimated
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerNCT07102381Jazz PharmaceuticalsPhase 2Recruiting2028-01-01Estimated
An Efficacy and Safety Study of LTG-001 Following AbdominoplastyNCT07102459Latigo BiotherapeuticsPhase 2Completed2026-01-07Actual
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)NCT07104383VKTXPhase 3Active not recruiting2027-07-01Estimated
VK2735 for Weight Management Phase 3NCT07104500VKTXPhase 3Active not recruiting2027-07-01Estimated
A Study to Assess Anktiva in Patients With Long Covid-19.NCT07108036IBRXPhase 2Recruiting2026-10Estimated
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to TrikaftaNCT07108153SIONPhase 2Completed2026-06-25Actual
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar DisorderNCT07116694BioXcel Therapeutics IncPhase 2Completed2025-10-07Actual
A Study to Examine Anktiva for the Treatment of COVID-19.NCT07123727IBRXPhase 2Recruiting2027-03Estimated
Study of Relapsed/ Refractory B-cell Non- Hodgkin LymphomaNCT07125872IBRXPhase 2Recruiting2027-05-25Estimated
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideNCT07128550VIRPhase 3Active not recruiting2026-12Estimated
SPN-817 Open-Label Extension Study in Adults With Focal Onset SeizuresNCT07141329SUPNPhase 2Recruiting2027-12-31Estimated
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionNCT07142811VIRPhase 2Active not recruiting2026-11Estimated
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)NCT07146022MANEPhase 3Active not recruiting2027-06Estimated
A Study of SPY072 in Rheumatic DiseaseNCT07148414SYREPhase 2Active not recruiting2026-10-31Estimated
Phase 2b Study of EVO756 in Adults With Atopic DermatitisNCT07150845EVMNPhase 2Active not recruiting2026-07Estimated
Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCsNCT07152379Cerus CorporationPhase 2Not yet recruiting2030-09-30Estimated
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)NCT07154706NUVBPhase 3Recruiting2030-08-30Estimated
A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)NCT07156578RYTMPhase 2Enrolling by invitation2028-04-15Estimated
Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19NCT07157007TRAWPhase 2Recruiting2026-02Estimated
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)NCT07157254RAREPhase 2Active not recruiting2030-01Estimated
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AMLNCT07157514Actinium PharmaceuticalsPhase 2, Phase 3Not yet recruiting2029-02Estimated
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)NCT07160634SLDBPhase 3Recruiting2029-01Estimated
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)NCT07161700Seaport TherapeuticsPhase 2Enrolling by invitation2027-05Estimated
Study of COYA 302 for the Treatment of ALSNCT07161999Coya TherapeuticsPhase 2, Phase 3Recruiting2027-01Estimated

Primary completion marks the end of data collection for the main study measures, not a results publication date.